Navigation Links
Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin(TM) in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.

In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy, the reduction in total nasal symptom score (TNSS). However, the TNSS data for placebo-treated patients was far lower than would be expected for the moderate to moderately severe patient population called for in the protocol. Low pollen counts in many of the regions during the time PreHistin was being tested may have resulted in low mean placebo symptom scores for the overall study population.

The trials showed that PreHistin was well tolerated and thus contributed positively to the safety record of PreHistin's active ingredient, cyanocobalamin.

A comparison of pre- and post-treatment blood levels of cobalamin demonstrated for the first time in a large study population that delivery of cyanocobalamin via sublingual lozenges resulted in significant increases in cobalamin blood levels.

Cobalis' Chief Scientific Officer Ernest Armstrong commented: "Showing a meaningful reduction in allergy symptoms when the symptoms never increased throughout the pollen season to the desired moderate to moderately severe level is next to impossible. It's like trying to prove that a pump can pump water out of a swimming pool when there is almost no water in the pool to begin with. Other pharmaceu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cobalis Expects to Report Phase III Top-Line Results in May
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)... 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... update and report second quarter 2014 financial results before ... 1, 2014. That same day, Arena will host a ... (5:30 a.m. Pacific Time). The conference ... callers and 914.495.8552 for international callers. Please specify to ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... 2012    Octapharma USA has submitted its Biological License ... Food and Drug Administration (FDA) with the goal of ... 2012. The FDA will evaluate the octaplasLG® ... patients who require replacement of multiple plasma coagulation factors. The ...
... 27, 2012  Ventana Medical Systems, Inc. (Ventana), a member of ... Food and Drug Administration (FDA) for the VENTANA Companion ... VENTANA iScan Coreo Au scanner running ... offering an FDA cleared Ki-67 image analysis algorithm for ...
Cached Medicine Technology:Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 2Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 3Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications 2
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Merrill ... of technology-enabled services for the financial, legal, healthcare ... virtual data room business, Merrill DataSite, has been ... presented by GrowthBusiness at the M&A Awards 2014 ... the achievements of entrepreneurs, management teams, advisors and ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... Treatment for lymphoma may lower men,s fertility, new research ... are cancers of the body,s white blood cells, often ... years. For men, treatment for these cancers can harm ... fertility within two years of treatment, the researchers cautioned ... this significant side effect before treatment begins. "While ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... man, who tested negative for the human form of the ... Diseases, in Bucharest// , after he exhibited flu like symptoms. ... H5N1 had infected the birds in the area. ... Bucharest national laboratory. The Ministry of Health has designated the ...
... rising obesity rates by 2010 will fall flat on its face, ... to a recent study// . Though local level work is going ... about the thrust given to this area. The public Health Minister, ... lots left to be done. Obesity has sent the NHS expenditure ...
... and Research Institutes, Inc (NDRI) in New York ... explored the role// of social supports, spirituality, religiousness, ... of recovery from addiction. The study reveals markedly ... as a decrease in stress when people were ...
... A 91-year-old woman in British Columbia died a lonely death after ... sons, is hopeful that his mom’s death// will bring about some ... ,The hospital separated Fanny Albo from her ailing husband who ... in Trail. Fanny Albo and her husband had been together for ...
... to a new Japanese study appearing in the current ... green tea daily may help reduce risk of dementia,.// ... related with the risk of having cognitive impairment in ... , Dr. Shinichi Kuriyama of Tohoku University Graduate ...
... Germany has reported that regular peelings and scrubbing with a ... the skin is stretched during pregnancy. // ,Peelings and ... magazine said. The same is true of massages. ... use of certain substances can help. ...
Cached Medicine News:Health News:Drug Addiction Recovery Buffered by Spirituality 2
Accommodates either eye. Slotted, malleable aluminum surface. Correct size holes produce ideal pin hole effect. Packaged 50 per box....
Blue plastic shield for reduced glare. Packaged 12 per box....
Non-reflective black anodized aluminum. Selection of five pin hole sizes (0.8 mm to 1.5 mm). Overall length: 4.0 inches....
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Medicine Products: